Leading Infectious Disease Biomaterial Manufacturer

Copan FLOQSwab® and Liquid Control Products
- Clinical Diagnostics,
- Proficiency Programs,
- Training, Verification and Development
Antigens for Diagnostic Test Manufacturers
Viral Transport Medium – DxTM™

Imagine there’s no cervical cancer. It’s easy, if we try.

In Ontario, health expenditures now exceed $87 billion per year and comprise over 40 per cent of overall spending. Such expenses are growing faster than our per capita productivity and show no signs of slowing down.

Microbix’s Corporate Presentation

Profitable growth from supporting next generation Diagnostics. Click below to download..

Microbix Reports Results for Q2 Fiscal 2025

Microbix reports results for its second quarter and first half of fiscal 2025 ended March 31, 2025 (“Q2” and “H1”). Sales for Q2 and H1 reflected differential growth between Antigens (up) and QAPs™ (down), alongside a markedly-improved gross margin.

QAPS

Why choose Microbix Quality Assessment Products (QAPs)? Find out more.

infectious-diseas-antigens-3_55600834-e67d-4aa2-ad6b-59096ce3b3c8

INFECTIOUS DISEASE ANTIGENS

Microbix produces one of the world’s broadest range of infectious disease antigens.

PARTNERSHIP OPPORTUNITIES

Microbix has a partnership opportunity. Check it out here.

Our Commitment to Quality

Our quality process ensures our customers receive products that meet and exceed their needs and expectations. Our quality management system takes into consideration regulatory requirements that are applicable to the type of products we manufacture and the industries we serve.